BridgeBio Pharma (BBIO) Prepaid Assets (2018 - 2026)

BridgeBio Pharma has disclosed Prepaid Assets across 9 years of filings, most recently posting $62.9 million for Q1 2026.

• Prepaid Assets for Q1 2026 came in at $62.9 million, up 77.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.9 million (up 77.95% YoY), and the FY2025 annual result was $44.1 million, up 26.39% from the prior year.
• Prepaid Assets came in at $62.9 million for Q1 2026 at BridgeBio Pharma, up from $44.1 million in the prior quarter.
• In the past five years, Prepaid Assets ranged from a high of $62.9 million in Q1 2026 to a low of $20.5 million in Q2 2023.
• The 5-year median for Prepaid Assets is $32.8 million (2022), against an average of $34.8 million.
• Across the five-year window, Prepaid Assets slumped 37.27% in 2023 and surged 112.14% in 2025, its largest moves.
• BridgeBio Pharma's Prepaid Assets stood at $21.9 million in 2022, then grew by 10.87% to $24.3 million in 2023, then jumped by 43.46% to $34.9 million in 2024, then advanced by 26.39% to $44.1 million in 2025, then jumped by 42.76% to $62.9 million in 2026.
• The last three Prepaid Assets figures came in at $62.9 million (Q1 2026), $44.1 million (Q4 2025), and $52.4 million (Q3 2025), per Business Quant data.